Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... 2014  Commonwealth Cornerstone Group (CCG) today announced the completion ... Tuesday to help fund the expansion and consolidation of healthcare ... Sharon . PHN is the largest ... . It is the largest employer in Sharon,s ... on staff. Currently, PHN Sharon offers scattered services ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Reportlinker.com announces that a new ... its catalogue: European ... Suppliers http://www.reportlinker.com/p0651441/European-Chemical-Market-Strategic-Assessments-of-Leading-Suppliers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug ... chemical industry executives with strategically significant ...
... Oct. 5, 2011 Reportlinker.com announces ... is available in its catalogue: ... Strategic Assessments of Leading Suppliers ... This report provides industry executives ...
Cached Medicine Technology:European Chemical Market: Strategic Assessments of Leading Suppliers 2European Chemical Market: Strategic Assessments of Leading Suppliers 3European Chemical Market: Strategic Assessments of Leading Suppliers 4European Chemical Market: Strategic Assessments of Leading Suppliers 5European Chemical Market: Strategic Assessments of Leading Suppliers 6European Chemical Market: Strategic Assessments of Leading Suppliers 7European Chemical Market: Strategic Assessments of Leading Suppliers 8Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 2Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 3Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 4Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 5Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 6Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 7
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier ... special occasion outfits, unveils 65 new bridesmaid dresses ... discounted prices, up to 80% off. , Yunx.co.uk’s dresses ... fashionable designs, gorgeous looks and delicate craftsmanship. These new ... devoted to designing and offering high-quality women’s dresses with ...
(Date:12/24/2014)... December 24, 2014 Mike Billings ... down with Derek Fenwick, PT, MBA, GCS, Director ... will stem from the passing of the Improving ... Act). In this taping of the Infinicast, the two ... of the Social Security Act to standardize post-acute assessment ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... C infection does not contribute to mental decline in people ... have made it possible for people with HIV to survive ... swings and other types of mental impairment as they age, ... with other viruses -- a common problem in people with ... suspects has been the hepatitis C virus, which infects about ...
(Date:12/24/2014)... (HealthDay News) -- Adults who experienced childhood abuse ... headaches, suggests a study published online Dec. 24 ... maltreatment can have long-lasting effects, like associated medical ... author Dawn Buse, director of behavioral medicine at ... in a journal news release. "When managing ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... HEIGHTS, N.J., Oct. 27 Authentidate,Holding Corp. ... of secure workflow,management software and web-based services, ... healthcare agency, has implemented Authentidate,s,Inscrybe Healthcare service ... its extensive customer base in both Ohio ...
... virtually no gastrointestinal, side effects for people who need ... ... CHICAGO, Oct. 27 Announced today at the American,Dietetic ... offers both heme (protein-based iron) and non-heme,iron (plant-based iron) ...
... Frost & Sullivan is,pleased to present the ... Innovation Award to Lifeblood Medical. This is,in recognition ... a,myriad of advantages and has led to the ... solution. In addition to human,organ preservation, Lifeblood Medical,s ...
... to be Used in Early Lines of,Therapy, ... Resources, WALTHAM, Mass., Oct. 27 ... and advisory firms focusing on pharmaceutical and,healthcare ... the leading biologic for Crohn,s disease, but,Abbott/Eisai,s ...
... Across States, WASHINGTON, Oct. 27 Sixty-three percent ... Survey,indicated they have implemented Leapfrog,s Never Events Policy which,describes ... error --,that should never happen to a patient -- ... 2007, the policy,s first year., Leapfrog,s hospital survey ...
... November 1, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Researchers analyzed ... and 22,863 adults,who received transplantation to determine the best ... posttransplant,mortality caused by differences in donor type was vastly ...
Cached Medicine News:Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 2Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 3Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 4Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 3Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 4Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:More Hospitals Adopting Leapfrog Group's 'Never Events' Policy Which Inculdes Apologies, Reporting, and Waiving Costs 2Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2
Adjustable Velcro© closures at crown and behind the neck distinguish this immediate post-op face and chin garment for maximum support and compression....
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Medicine Products: